VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
Stock Information for VBI Vaccines Inc.
Loading
Please wait while we load your information from QuoteMedia.